The analysis in the CN Aβ-/Tau- participants was not significant both in ADNI (rho =  − 0.13, p = 0.067; Fig. 2A) and BioFINDER-1 (rho = 0.027, p = 0.7; Fig. 2B), suggesting that the association between MWF and tau-PET scores is robust only in the group with biomarker evidence of AD. Here, MAPT is linked to Alzheimer disease.